Paz-Ares, Luis <br/><br/>
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Mar 2013 
 - 329-37 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e31827ce554  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adenocarcinoma, Bronchiolo-Alveolar--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carboplatin--administration & dosage<br/>Carcinoma, Large Cell--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage<br/>Prognosis<br/>Survival Rate